OncoMatch/Clinical Trials/NCT05659056
Neoadjuvant Study With Pyrotinib and Trastuzumab and Abraxane in Patients With HER2-enriched Breast Cancer
Is NCT05659056 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Pyrotinib, trastuzumab, paclitaxel-albumin for breast cancer.
Treatment: Pyrotinib, trastuzumab, paclitaxel-albumin — Breast cancer is kind of highly heterogeneous tumor. The patients with the same stage and with the same treatment regimen, their prognosis varies greatly, mainly due to the different phenotypes of breast cancer and different sensitivities to drug therapy. PMA50 and BluePrint classification divides breast cancer into other inherent subtypes: Luminal A, Luminal B, HER2-enriched (HER2-E) and Basal-like. Previous studies have shown that these patients with inherent subtype of HER2-enriched are more likely to obtain higher pCR after anti-HER2 therapy. And more study and meta analysis had demonstrated the higher pCR is closely related to EFS. The genetic and molecular typing of breast cancer is closely related to the prognosis of breast cancer, so it is imperative to seek a new treatment regimen for precision treatment and maximize the therapeutic benefit of HER2-enriched patients.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Biomarker criteria
Required: HER2 (ERBB2) overexpression (IHC 3+ or FISH+)
HER2 positive (HER2+++ by IHC or FISH+)
Disease stage
Required: Stage EARLY STAGE, III
Excluded: Stage IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Lab requirements
Kidney function
organs are functioning normally, like the renal function
Liver function
organs are functioning normally, like the liver function
Cardiac function
baseline left ventricular ejection fraction (LVEF)≥55% measured by ECHO
The organs are functioning normally, like the liver function, the renal function， and the baseline left ventricular ejection fraction (LVEF)≥55% measured by ECHO
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify